Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Korhan Raif

Internal Medicine Barry, IL Medical Doctor

NPI 1184697476 CMS profile 53081

868 Mortimer St, Barry, IL 62312

Open in the dashboard

General payments

$8,665

534 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Korhan Raif of Barry, IL is reported in the CMS Open Payments database as having received $8,665 across 534 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,112 64
2024 General $934 54
2023 General $1,100 65
2022 General $1,250 74
2021 General $1,895 116
2020 General $836 59
2019 General $1,539 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Korhan Raif
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Korhan Raif were reported at $1,112. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Korhan Raif Internal Medicine median Middle half National median
2019 $1,539 $159 $48–$570 $163
2020 $836 $119 $33–$402 $114
2021 $1,895 $135 $37–$521 $132
2022 $1,250 $141 $42–$496 $149
2023 $1,100 $149 $45–$519 $160
2024 $934 $154 $47–$537 $164
2025 $1,112 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,876 124 payments
  2. Lilly USA, LLC $880 60 payments
  3. AstraZeneca Pharmaceuticals LP $733 39 payments
  4. Pfizer Inc. $622 47 payments
  5. Amgen Inc. $578 32 payments
  6. E.R. Squibb & Sons, L.L.C. $482 30 payments
  7. Astellas Pharma US Inc $409 18 payments
  8. Teva Pharmaceuticals USA, Inc. $280 14 payments
  9. Novartis Pharmaceuticals Corporation $263 13 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $247 17 payments
  11. Other $2,295 140 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,383 530 payments
  2. Education $282 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,258 99 payments
  2. RYBELSUS $1,083 77 payments
  3. FARXIGA $487 25 payments
  4. ELIQUIS Cardiovascular $482 30 payments
  5. ELIQUIS Cardiovascular;Metabolic Disease $452 30 payments
  6. MOUNJARO $370 24 payments
  7. JARDIANCE $330 24 payments
  8. EVENITY $284 16 payments
  9. Repatha $274 15 payments
  10. Tresiba $264 15 payments
  11. Other $6,647 421 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 225 drugs

Part D claims

20,359

Median for Internal Medicine: 777

Drug cost

$1,406,455

Median for Internal Medicine: $73,373

Branded share of claims

23.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 398 $210,114
Jardiance Empagliflozin Brand 184 $126,883
Ozempic Semaglutide Brand 91 $96,158
Trulicity Dulaglutide Brand 100 $95,089
Xarelto Rivaroxaban Brand 180 $83,257
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 77 $60,782
Nuplazid Pimavanserin Tartrate Brand 12 $59,957
Farxiga Dapagliflozin Propanediol Brand 62 $43,572
Myrbetriq Mirabegron Brand 52 $40,875
Rexulti Brexpiprazole Brand 56 $40,443

The 10 drugs with the highest cost, of 225 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$4,321

Medicare's payments for the services billed

Medicare patients

186

Average age 75

Services billed

246

107 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Ischemic heart disease 37%
Diabetes 35%
COPD 33%
Atrial fibrillation 23%
Chronic kidney disease 23%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $96
$96 — —
Ozempic
  • Novo Nordisk Inc $96
$96 91 —
MOUNJARO
  • Lilly USA, LLC $84
$84 27 —
ZEPBOUND
  • Lilly USA, LLC $64
$64 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

534 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record